AbbVie Q3 adj EPS $2.95 (down 19.4%); raises FY23 and FY24 guidance; dividend up 4.7%

AbbVie Inc.

2023-Q3 EPS reported $2.26 revenue$40,017,000,000

Q3 GAAP diluted EPS $1.00 (down 54.8% YoY); adjusted diluted EPS $2.95 (down 19.4%); net rev $13.93B (down 6.0%).
Immunology down 11.3% as Humira fell 36.2%; Skyrizi up 52.1% and Rinvoq up 59.8% drove growth in other segments.
Raises 2023 adj EPS guidance to $11.19-$11.23 from $10.86-$11.06; 2024 floor raised to $11.00 from $10.70.
Dividend increased 4.7% to $1.55/quarter; payable Feb 15, 2024 to holders of record Jan 16, 2024.
Records $2.1B pre-tax impairment on Imbruvica intangible due to IRA price negotiation; remaining carrying value $1.8B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.